Christie D J, Leja D N, Carlson D L, Swinehart C D
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55455.
J Lab Clin Med. 1993 Mar;121(3):437-43.
The platelet-activating properties of plasma containing multispecific HLA antibodies were studied in plasma from several persons stimulated by platelet or red blood cell transfusion or by pregnancy. Antibodies were characterized by their lymphocytotoxic effects and by a monoclonal antibody antigen--capture enzyme-linked immunoassay. Plasma from each patient induced dose-dependent aggregation and release of adenosine triphosphate with antigen-positive platelet-rich plasma. Plasma from three patients induced normal aggregation and adenosine triphosphate release with platelet-rich plasma from donors who had taken platelet inhibiting medications (e.g. aspirin, piroxicam). In contrast, these platelets failed to release adenosine triphosphate when stimulated with 5 mumol/L adenosine diphosphate. Platelets were fully activated when saturated with HLA antibodies from one patient, although little or no stimulation was observed at 50% saturation suggesting that additional plasma cofactors and/or a threshold of bound antibody were required for activation. With a murine monoclonal antibody specific for P-selectin and antimurine immunoglobulin G labeled with iodine 125, plasma from each patient was found to induce P-selectin expression that was approximately 50% of that induced by 0.2 U/ml thrombin. Expression on platelets of P-selectin induced by plasma from one patient was independent of whether the donor had taken aspirin. Purified immunoglobulin G from this same patient stimulated platelet activation, as did the patient's serum, but no activation was observed with F(ab')2 fragments prepared from the immunoglobulin G. These studies demonstrate that HLA antibodies (1) mediate expression of P-selectin on the platelet surface, (2) are as potent as thrombin in activating platelets previously exposed to antiinflammatory agents, and (3) require an intact Fc domain to activate platelets.
我们研究了含有多特异性 HLA 抗体的血浆的血小板激活特性,这些血浆来自因输注血小板或红细胞或怀孕而受到刺激的数人。通过淋巴细胞毒性作用以及单克隆抗体抗原捕获酶联免疫测定对抗体进行表征。每位患者的血浆均可诱导抗原阳性富血小板血浆产生剂量依赖性的聚集及三磷酸腺苷释放。来自三名患者的血浆可诱导服用血小板抑制药物(如阿司匹林、吡罗昔康)的供体的富血小板血浆出现正常聚集及三磷酸腺苷释放。相比之下,这些血小板在用 5 μmol/L 二磷酸腺苷刺激时未能释放三磷酸腺苷。当用一名患者的 HLA 抗体饱和时,血小板被完全激活,不过在 50% 饱和时几乎未观察到刺激作用,这表明激活需要额外的血浆辅因子和/或结合抗体的阈值。使用针对 P-选择素的鼠单克隆抗体以及用碘 125 标记的抗鼠免疫球蛋白 G,发现每位患者的血浆均可诱导 P-选择素表达,其表达量约为 0.2 U/ml 凝血酶诱导量的 50%。一名患者的血浆诱导的血小板上 P-选择素的表达与供体是否服用阿司匹林无关。来自同一名患者的纯化免疫球蛋白 G 以及该患者的血清均可刺激血小板激活,但从免疫球蛋白 G 制备的 F(ab')2 片段未观察到激活作用。这些研究表明,HLA 抗体:(1) 介导血小板表面 P-选择素的表达;(2) 在激活先前接触过抗炎药物的血小板方面与凝血酶一样有效;(3) 需要完整的 Fc 结构域来激活血小板。